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OBJECTIVES: Our aim was to identify important factors that
may inﬂuence hypertensive patients’ compliance with treatment
from the patient’s perspective. METHODS: This qualitative
study was carried out at a university hospital in Singapore.
Hypertensive patients over 21 years old and who have been
treated for over 3 months were invited to participate in a semi-
structured interview. In the interview, participants were asked
about their experience in following the treatment. The Morisky
scale was used to measure patient’s compliance score. RESULTS:
Most of the participants exhibited a positive attitude toward
hypertension, claiming that their lifestyle was normal and not
inﬂuenced by hypertension. Participants were aware of the
importance of compliance with medication and risks of uncon-
trolled hypertension; despite some participants did not know the
normal value of blood pressure. Forgetfulness was found as an
important factor to affect patients’ compliance. Other potentially
inﬂuencing factors included an unsatisfactory clinical encounter,
such as physician’s time constraints during consultation, long
waiting time in clinic and reﬁlling prescriptions. The cost of
treatment was another factor, especially among retiree partici-
pants. CONCLUSION: Participants showed a strong willingness
to control their blood pressure. Patients have been given
adequate knowledge about the risks of hypertension. Strategies
to counter negative inﬂuencing factors (such as unsatisfactory
clinical encounter and cost of treatment) should be developed to
improve patients’ compliance with medication for better clinical
and economic outcomes.
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DOES A SINGLE PILL COMBINING AMLODIPINE AND
ATORVASTATIN OFFER GREATER LONG-TERM ADHERENCE
BENEFIT OVER LOW-COST GENERIC 2-PILL CALCIUM
CHANNEL BLOCKER/STATIN REGIMENS?
Patel BV1,Tang SSK2, Leslie RS1, Nichol MB3, Solomon HA2,
Trainer JB2, Foody JM4
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OBJECTIVES: To assess whether single-pill amlodipine besylate/
atorvastatin calcium (SPAA) use achieves greater adherence than
other, 2-pill calcium channel blocker (CCB) + statin regimens
stratiﬁed by brand/generic status using records of drug beneﬁts
managed by a large U.S. Pharmacy Beneﬁt Management
company. METHODS: Patients (N = 3,561) newly initiated on
either a CCB or a statin within 30 days of each other were
followed for 1 year. The 2-pill CCB + statin group (including
patients on amlodipine + atorvastatin) was sub-divided by
brand/generic status. Adherence (proportion of days covered
[PDC]) was based on the days that both antihypertensive and
lipid-lowering drugs were supplied, and was considered achieved
if PDC was 80%. Persistence was deﬁned as the number of
days on therapies until the ﬁrst 30-day gap. Propensity-score
weighted logistic regression and proportional hazard models
were used to adjust for demographics and key baseline pharmacy
utilization variables including copay. RESULTS: At baseline,
mean age was 63 years, 52% were female, 11% utilized coronary
vasodilators, 30% utilized anti-diabetics; mean number of
other baseline medications was 8. Baseline characteristics
varied between cohorts. The percentages of patients achieving
PDC  80% were: SPAA 63.9%, Branded CCB + Branded statin
(BB) 38.9%, Branded CCB + Generic statin (BG) 37.8% and
Generic CCB + Generic statin (GG) 32.1%. SPAA patients were
three times as likely to achieve adherence versus BB (OR = 3.39;
CI: 3.06–3.75; P < 0.0001) and BG (OR = 3.14; CI: 2.84–3.47;
P < 0.0001); and more than twice as likely versus GG
(OR = 2.77; CI: 2.50–3.06; P < 0.0001). SPAA patients were less
likely to discontinue therapies versus BB (HR = 0.52; CI: 0.49–
0.56; P < 0.0001), BG (HR = 0.52; CI: 0.49–0.55; P < 0.0001),
and GG (HR = 0.59; CI: 0.55–0.63; P < 0.0001). CONCLU-
SION: In this nationally representative, insured population,
patients receiving the single-pill were more likely to achieve
adherence versus 2-pill CCB + statin regimens even if a lower-
cost generic was used.
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THE IMPACT OF LOWERING SYSTOLIC BLOOD PRESSURE
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OBJECTIVES: Explore the impact of lowering Systolic Blood
Pressure (SBP) on the Quality of Life (QoL) of Greek hyperten-
sive patients undergoing pharmacotherapy and determine spe-
ciﬁc factors that contributed to the improvement of the patients’
QoL during the period of treatment. METHODS: Data was
derived from the PharmacoECOnomic Assessment of Prognostic
Risk Occupational Survey (ECON-APROS). The ECON-APROS
study was a cross-country prospective study that involved the
1-year monitoring of hypertensive patients undergoing pharma-
cotherapy, in terms of medical, economic and quality-of-life
aspects. Out of total 1640 patient records collected, 1511 met the
inclusion criteria of the study. Data regarding the patients’ self
reported QoL were collected at the initiation and at the termi-
nation of the 1-year period. Patients’ self reported outcomes were
based on a questionnaire combining generic and speciﬁc quality
of life instruments. The statistical analysis was based on the
logistic regression models in order to explore factors that
inﬂuence patients’ QoL. RESULTS: A total of 29.8% patients
reported that their overall QoL has been improved during the
1-year period of treatment, while another 9.35% reported dete-
rioration. Moreover, logistic regression showed that the decrease
in the patients’ SBP after 1 year of pharmacotherapy had a
statistically signiﬁcant inﬂuence in the improvement of the QoL
(OR 1.021, 95%C.I. 1.012–1.030, p < 0.0001) as opposed to the
other variables inserted in the model (i.e. difference in the Dias-
tolic Blood Pressure after 1 year of treatment, co-morbidity, BMI,
age, sex, marital status, place of residence, private insurance,
percentage of the patients’ participation in drug costs). CON-
CLUSION: Lowering of the Systolic Blood Pressure during the
course of anti-hypertensive treatment was shown to have a sig-
niﬁcant impact on the hypertensive patients’ Quality of Life. The
ECON-APROS is the ﬁrst study to address such issues in the
Greek health care setting and sets the foundations for further
analysis.
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